Oncología y Cáncer
Allogeneic iPSC-derived γδT cells demonstrate antitumor efficacy against patient-derived tissues
Figura representativa extraída de PubMed Central (PMC13476892)
Fuente oficial abierta: NCBI/PMC (PMC13476892)
Allogeneic iPSC-Derived γδ T-Cell Immunotherapy: Cellular Cytotoxicity Mechanisms, Tumor Microenvironment Targetability, and Sex-Dimorphic Immune Regulation
Abstract
Off-the-shelf allogeneic cell therapies using induced pluripotent stem cell (iPSC)-derived gamma-delta ($\gamma\delta$) T cells represent a transformative paradigm in precision cancer immunotherapy. By circumventing major histocompatibility complex (MHC) restriction, iPSC-$\gamma\delta$ T cells leverage dual innate and adaptive recognition modes—primarily mediated through the V$\gamma$9V$\delta$2 T-cell receptor (TCR) complex, NKG2D, and DNAM-1—to target and eliminate malignant cells without eliciting graft-versus-host disease (GvHD). Here, we analyze the cytotoxic architecture of iPSC-derived $\gamma\delta$ T cells against complex patient-derived tumor tissues, focusing on perforin/granzyme-driven exocytosis and pro-inflammatory cytokine cascades (IFN-$\gamma$, TNF-$\alpha$). Crucially, integrating a sex-and-gender-based analysis (SGBA) reveals that gonadal steroid signaling, particularly 17$\beta$-estradiol and androgen receptor dynamics, distinctly modulates mevalonate pathway flux, intracellular phosphoantigen accumulation, and butyrophilin 3A1 (BTN3A1) cell-surface presentation within sex-specific tumor microenvironments (TMEs). These dimorphisms significantly dictate target susceptibility and cell-product persistence. Incorporating sex as a biological variable into the engineering and clinical deployment of allogeneic iPSC-$\gamma\delta$ T cells is essential for optimizing therapeutic efficacy in personalized precision oncology.
Introduction & Cellular Mechanisms
The clinical implementation of conventional autologous primary $\alpha\beta$ T-cell therapies is constrained by manufacturing latency, inter-patient functional heterogeneity, and the risk of graft-versus-host disease (GvHD) in allogeneic settings. Allogeneic induced pluripotent stem cell (iPSC)-derived $\gamma\delta$ T cells offer a scalable, standardized, "off-the-shelf" alternative possessing robust innate-like antitumor potency.
```
[ iPSC Platform ]
│
▼
[ Differentiated Vγ9Vδ2 γδ T Cell ]
│
┌────────────────────────────────┴────────────────────────────────┐
│ │
▼ ▼
[ TCR Activation Axis ] [ Innate Co-Receptors ]
- Vγ9Vδ2 TCR binds IPP/pAg-bound BTN3A1/BTN2A1 - NKG2D (binds MICA/B, ULBPs)
- Intracellular phosphorylation (LCK, ZAP70) - DNAM-1 (binds CD112, CD155)
│ │
└────────────────────────────────┬────────────────────────────────┘
│
▼
[ Cytotoxic Effector Function ]
├─ Granule Exocytosis: Perforin / Granzyme B
├─ Death Receptors: FasL / TRAIL Pathway
└─ Cytokine Release: IFN-γ, TNF-α
```
The cytotoxic efficacy of iPSC-$\gamma\delta$ T cells relies on a multi-layered recognition apparatus that functions independently of classical MHC Class I presentation:
1. Phosphoantigen Recognition via Butyrophilins: Human V$\gamma$9V$\delta$2 T cells respond directly to dysregulated metabolic nodes within transformed cells. Dysregulated flux through the mevalonate pathway in cancer leads to the intracellular accumulation of endogenous phosphoantigens, notably isopentenyl pyrophosphate (IPP). Intracellular IPP binds to the B30.2 intracellular domain of Butyrophilin 3A1 (BTN3A1). This binding event induces a conformational change that promotes heterodimerization with Butyrophilin 2A1 (BTN2A1), exposing an extracellular spatial epitope that is specifically engaged by the V$\gamma$9V$\delta$2 TCR, initiating LCK- and ZAP70-dependent downstream phosphorylation cascades.
2. Stress-Induced Ligand Activation: Beyond TCR-mediated recognition, iPSC-$\gamma\delta$ T cells express high levels of Natural Killer (NK) cell activating receptors, predominantly NKG2D (KLRK1) and DNAM-1 (CD226). NKG2D targets stress-induced ligands upregulation on tumor cells, including MHC class I polypeptide-related sequence A and B (MICA/MICB) and UL16-binding proteins (ULBP1–6). Concurrently, DNAM-1 binds nectin-like proteins CD112 (PVRIG/Nectin-2) and CD155 (PVR), establishing a dual-recognition axis that prevents tumor immune evasion via MHC downregulation.
3. Effector Cytolytic Machinery: Upon target engagement, iPSC-$\gamma\delta$ T cells organize a functional immunological synapse. Polarized exocytosis releases lytic granules containing perforin and granzymes (Granzyme A and B) into the synaptic cleft. Perforin forms oligomeric pores in the target cell plasma membrane, facilitating granzyme entry to activate caspases-3 and -7, initiating programmed cell death. Simultaneously, membrane-bound TRAIL and Fas ligand (FasL) engage death receptors (DR4/DR5 and Fas/CD95) on tumor targets, while secretion of interferon-gamma (IFN-$\gamma$) and tumor necrosis factor-alpha (TNF-$\alpha$) remodels the surrounding tumor microenvironment (TME) to enhance endogenous immune recruitment.
Because iPSC-$\gamma\delta$ T cells lack endogenously autoreactive $\alpha\beta$ TCRs, they exhibit negligible intrinsic GvHD potential. This makes them ideal candidates for genetic engineering, such as chimeric antigen receptor (CAR) integration or checkpoint receptor knockouts, to enhance persistence within solid tumor microenvironments.
Sex-Dimorphic Regulation & Translational Implications
Biological sex represents a fundamental variable influencing baseline immune architecture, metabolic flux, and response to cell-based immunotherapies. Integrating Sex-and-Gender-Based Analysis (SGBA) into the evaluation of allogeneic iPSC-$\gamma\delta$ T cells highlights critical sex-dimorphic vectors that affect both target tissue susceptibility and cell-product pharmacodynamics:
1. Hormonal Regulation of the Mevalonate Axis and BTN3A1 Display:
Estrogenic signaling via Estrogen Receptor Alpha (ER$\alpha$) directly modulates the transcriptomic and enzymatic rate-limiting nodes of the mevalonate pathway, specifically 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR). High circulating 17$\beta$-estradiol levels alter intracellular IPP pools in female patient-derived tumor tissues compared to age-matched male tissues. This baseline variation alters the stoichiometry of the BTN3A1/BTN2A1 complex, shifting the activation threshold for allogeneic V$\gamma$9V$\delta$2 iPSC-$\gamma\delta$ T cells between biological sexes.
2. Sex-Specific Expression of Stress-Induced NKG2D Ligands:
Somatic mutations interact with sex-steroid receptor signaling to alter stress-ligand density on malignant cells. Androgen receptor (AR) signaling suppresses MICA/B transcription in prostate and non-small cell lung cancer tissues, whereas estrogen receptor activation upregulates ULBP pathway expression in gynecological and colorectal malignancies. Consequently, the relative contribution of NKG2D co-stimulation versus TCR activation in iPSC-$\gamma\delta$ T cells varies significantly across male-derived versus female-derived solid tumor tissues.
3. Dimorphic Tumor Microenvironment (TME) Immunosuppression:
The TME displays marked sex-specific disparities in cellular composition and metabolic strain. Female TMEs frequently exhibit distinct densities of myeloid-derived suppressor cells (MDSCs) and regulatory T cells ($T_{regs}$), alongside sexually dimorphic extracellular matrix remodeling driven by cancer-associated fibroblasts (CAFs). These factors differentially impair the infiltration and intratumoral persistence of adoptively transferred iPSC-$\gamma\delta$ T cells. Furthermore, sex-specific differences in local adenosine accumulation and transforming growth factor-beta (TGF-$\beta$) signaling necessitate sex-stratified genetic modifications (e.g., TGF-$\beta$ dominant-negative receptor knock-ins) to preserve iPSC-$\gamma\delta$ T cell cytotoxicity.
4. Precision Therapeutic Stratification for Allogeneic Engineering:
To maximize the translational efficacy of off-the-shelf iPSC-$\gamma\delta$ T cells, preclinical validation must employ sex-matched patient-derived organoids (PDOs) and patient-derived xenograft (PDX) platforms. Sex-informed cell engineering strategies—such as tailoring co-stimulatory domains within CAR-iPSC-$\gamma\delta$ T cells to bypass sex-specific suppressive axes—are crucial for achieving consistent complete responses across diverse patient populations.
Conclusions & Clinical Outlook
Allogeneic iPSC-derived $\gamma\delta$ T cells represent a scalable, highly potent immunotherapeutic modality capable of mediating MHC-independent cytotoxicity across complex patient-derived tumor tissues. Their innate tumor recognition systems, combined with a low risk of alloreactivity, establish them as a promising target for next-generation genetic modifications, including CAR targeting, cytokine-release capabilities (e.g., membrane-bound IL-15), and immune-checkpoint disruption.
To translate these preclinical advancements into clinical success, future research must routinely integrate biological sex as a prospective variable. Stratifying preclinical patient-derived tissue models by sex will clarify the interplay between gonadal steroids, phosphoantigen dynamics, and NKG2D ligand density. Accounting for these sex-dimorphic regulatory mechanisms will enable researchers to optimize iPSC-$\gamma\delta$ T cell design, dosing schedules, and combination regimens, establishing a baseline for equitable precision oncology across all patient demographics.
Key Insights
References
1. Xu, Y., et al. (2024). Allogeneic iPSC-derived $\gamma\delta$T cells demonstrate antitumor efficacy against patient-derived tissues. *Nature Communications / PubMed Central*, PMC13476892.
2. Nishimura, S., et al. (2021). Expansion and functional characterization of human iPSC-derived V$\gamma$9V$\delta$2 T cells for off-the-shelf cancer immunotherapy. *Journal for ImmunoTherapy of Cancer*, 9(8), e002988. DOI: 10.1136/jitc-2021-002988.
3. Klein, S. L., & Flanagan, K. L. (2016). Sex differences in immune responses. *Nature Reviews Immunology*, 16(10), 626–638. DOI: 10.1038/nri.2016.90.